Navigation Links
Novel Diabetes Drug Discovery Has Potential to Reverse Disease
Date:1/27/2009

ion as a therapeutic approach. Pancreatic islets contain four primary cell types and are responsible for producing insulin, amylin, glucagon and other hormones critical to maintaining normal glucose regulation. Current diabetes therapies, including insulin, help to control the disease but do not restore new islets. HIP addresses the underlying mechanism of the pathology of diabetes and represents a potentially curative approach to both, type 1 and 2 diabetes. If successful in human clinical trials, HIP-induced restoration of islet function has the potential to become a first-line treatment approach for diabetes and pre- diabetes.

About HIP

Human proIslet Peptide (HIP) is a 14-amino acid, stabilized human peptide that stimulates the signal pathways that induce new islet formation in the pancreas, without the use of stem cells. HIP creates new insulin-producing beta cells by generating new islets that contain alpha, beta, gamma and delta cells, all of which are necessary to regulate glucose metabolism. The core patent for the HIP technology was issued in July 2008.

About CureDM

CureDM is a Biotherapeutics company focusing on Diseases of Metabolism. CureDM has developed a proprietary platform technology using genomics and proteomics to identify bioactive components of gene products that are fundamental to address unmet medical needs. HIP is the first product derived from this process with other pipeline compounds under development. CureDM, Inc. is located in the Lankenau Institute for Medical Research at the Lankenau Hospital campus in Wynnewood, PA. For further information visit www.curedm.com

About Endocrine Practice

Endocrine Practice is the peer-reviewed journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists read by more than 6000 endocrinologists. The content of En
'/>"/>

SOURCE CureDM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis
2. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
3. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
4. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
5. Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
8. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
9. ScinoPharm Granted US Patent for Novel Crystal Forms
10. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
11. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... DUBLIN , Oct 24, 2014 ... the "Epigenetics Market by Product , Research Area ... report to their offering. In ... the basis of products, research areas, and end users. ... this report are enzymes, instruments & consumables, kits, and ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 New ... in the in vitro diagnostic (IVD) test industry, especially ... Information. The healthcare market researcher listed more than 25 testing ... could be the future of IVD products. Kalorama details the ... The Worldwide Market for In Vitro Diagnostic Tests ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
Breaking Biology Technology:Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 2Global Epigenetics (VLA, WBA, NBA, RTA, Rotary-Wing Aircraft) Market - Forecast to 2019 3Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4
... February 26 ScreenCancer AS, a Norwegian,company ... insurance,companies and individuals, today announced that it ... screening test to its European Cancer,Screening Program. ... a subsidiary of Quest Diagnostics Incorporated (NYSE: ...
... revolutionary Trusted LASIK Surgeons directory service and website at ... for consumers seeking to improve their vision and find ... chances of attaining 20-20 vision. What sets the ... process ensuring that only those who are among the ...
... 26 Syngenta announced today that the Board of ... Meeting on April 21, 2009, to name Stefan Borgas ... (45) is Chief Executive Officer of Lonza, one of ... life science industries, headquartered in Basel. Prior to joining ...
Cached Biology Technology:ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program 2ScreenCancer Adds InSure(R) FIT(TM) Colorectal Cancer Screening Test to European Cancer Screening Program 3Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 2Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 3Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 4Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 5Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 6Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 7Rick Fraunfelder, M.D. of the Casey Vision Correction Center in Portland, Oregon, Joins Elite Group of Surgeons Listed at Trusted LASIK Surgeons 8Syngenta Board Proposes Stefan Borgas to Become New Director 2
(Date:10/22/2014)... SAN JOSE, Calif. , Oct. 20, 2014 /PRNewswire/ ... with the United States Air Force Research Laboratory (AFRL), ... for Integrative Medicine (AzCIM) at the University of Arizona ... to receive research funding.  The AzCIM project,s goal is ... their ability to collect different volumes of sweat under ...
(Date:10/18/2014)... Among a group of 2,000 patients referred for ... a potential molecular diagnosis for 25 percent, including ... and new mutations contributing to disease, according to ... study is being released to coincide with the ... Whole-exome sequencing analyzes the exons or coding regions ...
(Date:10/17/2014)... release is available in German . ... a very few drugs. When treating overdoses, doctors are often ... especially difficult if there is a combination of drugs involved. ... and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux ... to find an answer to this question. "The task was ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... an important discovery that raises doubts concerning the viability ... warming, a projected $100 billion venture. Research performed ... Journal of Geophysical Research, suggests that ocean fertilization may ... in the atmosphere, a major contributor to global warming. ...
... Researchers at the University of Illinois have developed ... treatment and drug delivery. The highly permeable and ... the functional water channel protein Aquaporin Z into ... currently in the form of vesicles, show significantly ...
... Maryland, USA; 29 November 2007 Galapagos NV (Euronext ... (CFFT), the non-profit affiliate of the Cystic Fibrosis Foundation, ... treatments for cystic fibrosis. This new agreement between ... up to 5.5 million euros ($8.1 million U.S. dollars) ...
Cached Biology News:New research discredits $100B global warming 'fix' 2New research discredits $100B global warming 'fix' 3New research discredits $100B global warming 'fix' 4Researchers develop better membranes for water treatment, drug delivery 2Galapagos and Cystic Fibrosis Foundation Therapeutics announce drug discovery collaboration 2
... The Jouan RC10 series of vacuum ... product protection features allied to rapid and ... modules can be combined with oil-free or ... traps and a wide selection of rotors ...
... George Paxinos Affiliation: School of Psychology, The University ... Affiliation: Curtin University of Technology, Perth, Australia This ... of the rat brain. It is a ... revison and extension of the compact 3rd edition. ...
... kit. Includes configured Laptop PC with PCR ... MultiBlock satellite thermal Cycler (non-robotic). System ... software. Store/track run data. Gradient ... Outstanding uniformity. Advanced control algorithms for ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: